Skip to Content
May 17 2023
Reported €30.2 million in cash and cash equivalents as of March 31, 2023 PARIS and CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment
May 05 2023
Company agreed to term sheet as of May 3, 2023  PARIS and CAMBRIDGE, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘ Company ’’), today announced that the Company is entering into final contract negotiations after agreement to a non-binding term sheet for
Apr 11 2023
PARIS, April 11, 2023 (GLOBE NEWSWIRE) -- In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Paris, France, April 11, 2023 Market: Euronext Paris / Nasdaq Euronext
Feb 14 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) Name:DistributionId Value:8749207 --> Name:EnableQuoteCarouselOnPnr Value:False --> Name:IcbCode Value:4573 -->
Jan 11 2023
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS , Jan. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment: B ISIN code: